Abstract:Potential conflict of interest: Nothing to report. To the Editor: We read with great interest the article by Bessho et al., who demonstrated that, among the 15 genes uniquely expressed in the liver of patients with biliary atresia (BA), IL8 and LAMC2 were sufficient to distinguish subjects with BA from patients with non‐BA controls, with an accuracy of 95%.1 They conclude that hepatic expression of these two genes may serve as a biomarker of disease. Whereas we appreciate the findings, we would like to address a few issues that may help further clarify or confirm the findings. First, only 14 patients were included as non‐BA controls; the causes of disease were unknown for 64.3% (n = 9) (Supporting Table 1 of Bessho et al.). Moreover, 21.4% (n = 3) of the non‐BA controls were misclassified by IL8 and LAMC2 as BA (Supporting Table 2 of Bessho et al.). It is conceivable that some non‐BA diseases share a similar genetic signature or phenotypic traits with BA, and exhibit similar hepatic expression profiles. Indeed, as previously demonstrated, the IL‐8 level is higher in the BA and non‐BA groups than in normal controls, and the increased IL‐8 level is associated with the lymphocytic count and the degree of fibrosis in BA.2 Also, it has been known that viral infection can promote IL‐8 expression in the liver, which is associated with chronic liver disease.5 Thus, subjects with virus infection in the non‐BA groups might have a similar level of hepatic IL‐8 expression, compared with those in the BA group. In the present study, whether the false positivity by IL8 and LAMC2 observed in three patients in the non‐BA group was associated with infections with viruses such as rotavirus, cytomegalovirus, etc. is unknown. Second, it has been reported that IL‐8 mRNA increases in the liver, particularly in the late stage of BA (e.g., the degree of fibrosis represented by aspartate aminotransferase‐to‐platelet ratio index) and advanced age, and is associated with persistent jaundice, portal hypertension, and/or an increased inflammation and fibrosis in the liver.3 Thus, it is recommended that the patients included in the study be divided into different groups according to the degree of fibrosis (e.g., aspartate aminotransferase‐to‐platelet ratio index) and age (e.g., ≤60, 61‐90, and > 90days). Therefore, it would be interesting if Bessho et al. were to reassess their data by taking viral infection, the degree of fibrosis, and age into account. Alternatively, a larger case‐controlled study incorporating the above‐mentioned points is required.

Value of the Liver Function Test in Differential Diagnosis of Infantile Hepatitis Syndrome and Biliary Atresia

Clinical Value of Hepatobiliary Imaging at 6 H Combined with Serum ALP/γ-GT Ratio in the Diagnosis of Biliary Atresia

Diagnostic Values of Plasma Matrix Metalloproteinase-7, Interleukin-8, and Gamma-Glutamyl Transferase in Biliary Atresia

Utility of Liver Stiffness Measurement for Differentiating Biliary Atresia from Other Causes of Infantile Cholestasis

[Value of serum gamma-glutamyl transpeptidase combined with direct bilirubin in the diagnosis of biliary atresia in infants]

Value of Gamma-Glutamyl Transpeptidase for Diagnosis of Biliary Atresia by Correlation with Age.

Diagnostic Value of HA, PC-III, IV-C, and LN in Infants with Congenital Biliary Atresia

[The Diagnostic Value of Eight Serum Indices for Liver Fibrosis].

Serum Protein Markers Far Biliary Atresia

Metabonomics Reveals Metabolite Changes in Biliary Atresia Infants

Progress in Biomarkers Related to Biliary Atresia

The Clinical Value of Combined Biochemical Tests in Detecting Liver Diseases

Serum MMP-7 in the Diagnosis of Biliary Atresia

Diagnostic Value of Serum Total Bile Acid in Patients with Liver Cirrhosis

Key Histopathologic Features of Liver Biopsies That Distinguish Biliary Atresia From Other Causes of Infantile Cholestasis and Their Correlation With Outcome: A Multicenter Study

Validation of Aspartate Aminotransferase to Platelet Ratio for Diagnosis of Liver Fibrosis and Prediction of Postoperative Prognosis in Infants with Biliary Atresia.

Elevated Bile Acids In Newborns With Biliary Atresia (Ba)

Neonatal Dubin-Johnson Syndrome and Its Differentiation from Biliary Atresia

Comparative Study of ARFI and RTE Technique in Evaluating Liver Stiffness in Children with Biliary Atresia

The Diagnostic Value and Limitations of Total Serum Bile Acid Determined Enzymatically

Hepatic Expression of Interleukin 8 in Diagnosing Biliary Atresia